N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Description

The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.

Conditions

High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.

N10: Reduced Therapy for High-Risk Neuroblastoma

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Condition
High-risk Neuroblastoma
Intervention / Treatment

-

Contacts and Locations

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of NB as defined by histopathology, BM metastases plus high urine catecholamine levels, or positivity in MIBG scan.
  • * HR-NB, defined as MYCN-amplified stage L2/M/MS at any age and stage M in patients \>18 months old.
  • * No more than one prior cycle of HR-NB chemotherapy
  • * Age \<19 years.
  • * Signed informed consent indicating awareness of the investigational nature of this treatment.
  • * Severe dysfunction of major organs, i.e., renal, cardiac, hepatic, neurologic, pulmonary, hematologic, or gastrointestinal toxicity \> grade 2
  • * Inability to comply with protocol requirements
  • * Pregnancy

Ages Eligible for Study

18 Months to 19 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Brian Kushner, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2029-07-22